(HealthDay News) — For U.S. adults with gastroesophageal reflux disease (GERD), the risk for myocardial infarction (MI) is slightly elevated among those using proton pump inhibitors, according to a review published in PLOS ONE.
“Proton pump inhibitors (PPIs) have been associated with adverse clinical outcomes amongst clopidogrel users after an acute coronary syndrome. Recent pre-clinical results suggest that this risk might extend to subjects without any prior history of cardiovascular disease. We explore this potential risk in the general population via data-mining approaches,” John Cooke, MD, PhD, chair of cardiovascular sciences at the Houston Methodist Research Institute, and colleagues wrote.
The researchers examined more than 16 million clinical documents on 2.9 million individuals. They sought to assess the association between proton pump inhibitor usage and CV risk in the general population.
Overall, proton pump inhibitor users were found to be 16% more likely to suffer a MI than patients with chronic GERD who were not taking the drugs. H2-blockers were not linked to any increase in MI risk, the study authors noted
Cooke told HealthDay that recent lab research suggests that proton pump inhibitors can interfere with normal blood vessel function — a potential mechanism by which the drugs could affect MI risk.